US equities |
MU $953.19 ▼-3.62% NVDA $228.52 ▲+0.97% META $762.50 ▲+2.63% AAPL $341.27 ▲+0.09% MSFT $543.45 ▲+0.43% SNDK $1,482.33 ▼-0.34% AMD $605.53 ▲+1.90% SPCX $156.54 ▼-4.21%
FinancialContent

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

78.53 -0.71 (-0.90%)
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

News headline image
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
News headline image
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – 
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) Near the Top of Equities by Percentage Gain on 7/25
Via Investor Brand Network
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs